interesting - search results

If you're not happy with the results, please do another search

0 249

PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board

 In the world of pharmaceuticals, the approval of a new drug is largely a matter of its relative performance rather than an absolute performance. That is, the therapy in question doesn’t just have to work — it has to work as good, or better, than the treatments currently approved for a particular disease.

It’s a subtle but important nuance for up-and-coming biotech company PharmaCyte Biotech, Inc. (PMCB), which is not only developing what looks like a successful pancreatic cancer treatment, but a treatment that could indeed outperform the preferred therapies of Abraxane® plus gemcitabine (from Celgene Corporation), gemcitabine as a single agent (from Eli Lilly), and Tarceva® plus gemcitabine (made by Roche Holding subsidiary Genentech).

It’s not the potential spin on a lesser-used cancer drug — ifosfamide — that makes the PharmaCyte Biotech story so compelling right now, however. The story took an interesting and even more encouraging turn last week when PharmaCyte brought a pancreatic cancer veteran into the fold who also happens to have close ties with another one of the world’s leading authorities on the matter.

On Thursday of last week, PharmaCyte Biotech added Dr. Manuel Hidalgo to the company’s Scientific Advisory Board.

Dr. Hidalgo is one of Europe’s leading clinical and laboratory investigators in the field of pancreatic cancer. He presently heads the Gastrointestinal Cancer Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO). Dr. Hidalgo is also the Director of the Clara Campal Oncology Center in Madrid, in addition to holding a post as professor of Oncology at the University CEU San Pablo, in Madrid. Between 2001 and 2009, he was the Co-Director of both the Drug Development and Gastrointestinal Oncology Programs at Johns Hopkins University.

It’s expertise and experience that could prove invaluable to PharmaCyte, and yet, there’s more to the story.

Dr. Hidalgo is also a co-founder and Chairman of the international Pancreatic Cancer Research Team (PCRT), and works with co-founder Dr. Daniel Von Hoff, who also serves as the Chief Development Officer of Translational Drug Development or TD2.

Dr. Von Hoff is renowned for all of his contributions to pancreatic cancer treatments, but he was a critical part of the development of the aforementioned gemcitabine and Abraxane plus gemcitabine, the current top therapy choices of oncologists to fight pancreatic cancer, and the drugs PharmaCyte aims to outperform with its treatment of Cell-in-a-Box® plus low doses of the anticancer drug ifosfamide, in upcoming Phase 2b clinical trials in Australia.

Moreover, Dr. Hidalgo has himself participated in the development of several cancer drugs, including the combination chemotherapy of Abraxane plus gemcitabine. He also led the early-stage testing of temsirolimus as a treatment for advanced kidney cancer, and Tarceva, which in combination with gemcitabine is currently approved to treat non-small cell lung cancer in addition to advanced pancreatic cancer.

In light of his experience with Tarceva, gemcitabine and Abraxane (not to mention his association with Dr. Von Hoff via the international Pancreatic Cancer Research Team), access to Dr. Hidalgo’s insight should further increase the odds that PharmaCyte Biotech demonstrates comparable, or even better, efficacy when comparing its results to the results Tarceva, gemcitabine and Abraxane plus gemcitabine generally achieve as a means of fighting pancreatic cancer. Indeed, there may be nobody better suited to help develop a drug than one of the creators of the drugs that serve as the current standard of care for pancreatic cancer patients.

As for the results the company has already created using ifosfamide as a pancreatic cancer treatment that’s catalyzed by its Cell-in-a-Box platform, they’re encouraging to say the least. According to the company, in comparison to gemcitabine, the treatment increased median survival from 28 to 44 weeks and percentage of one-year survivors from 18% to 36% in its phase 1/2 trial. It’s no wonder the U.S. Food and Drug Administration (FDA) granted the drug/delivery combination an orphan drug designation at the end of last year.

With all of that being said, while PharmaCyte is initially taking aim at pancreatic cancer and is preparing for a phase 2b or “mini” phase 3 clinical trial using its Cell-in-a-Box platform as a means of delivering anticancer agent ifosfamide, one can’t help but wonder if the addition of Hidalgo to the Scientific Advisory Board will also lay the groundwork for the development of other cancer treatments. Dr. Hidalgo has already expressed interest in the Cell-in-a-Box technology as a means to treat other solid tumors, such as liver cancer, and the company itself has been fleshing out how Cell-in-a-Box could be best utilized to treat symptoms associated with all abdominal cancers, including malignant ascites fluid (currently in preclinical trials at TD2) and pain (preparing for a phase 1/2 clinical trial at TD2), and the company is exploring using its platform technology to treat brain tumors as well.

Whatever is in the cards, PharmaCyte Biotech clearly added a power-hitter to its roster last week.

Read more articles and our research report on PharmaCyte Biotech

About SmallCap Network

The SmallCap Network is an electronic publication committed to providing our readers with useful information on publicly traded companies. SmallCap Network sometimes contracts with third parties or publicly traded companies and receives compensation from them in the form of cash and sometimes restricted securities as payment for publishing information and opinion about the company and the trading market for their securities. Principals of the SmallCap Network may also purchase or sell securities of the companies in the open market from time to time. The positions that the SmallCap Network or its principals maintain in securities of the companies are disclosed here and should be considered in making an investment decision regarding companies mentioned on the SmallCap Network site. The SmallCap Network may be deemed to have a conflict of interest between its open market activity and positions in these securities and the timing of and opinions expressed in its publications concerning these companies. SmallCap Network has been compensated $10,000 and has been pledged a fee of $4,000 per month by a third party for market awareness and other advertising services on PMCB.

All statements and opinions expressed herein are those of the editors and staff of SmallCap Network and are subject to change without notice. The SmallCap Network maintains editorial control over its publications and the companies profiled therein do not have any editorial rights concerning the information published about them. No information contained in our website, e-mail communications or our publications should be considered as a solicitation to purchase or sell any of the securities mentioned. SmallCap Network, its principals or employees are not registered investment advisors or a registered securities broker dealer. We do not undertake or represent to make investment recommendations or to give advice pertaining to the purchase or sale of the securities mentioned in our web site, e-mail communications or publications. While we believe all sources of information provided by us and contained in our publication to be accurate and reliable, we cannot and do not guarantee the accuracy of information we received from third parties.

Furthermore, SmallCap Network has not independently verified such information provided within our publication. Readers are encouraged to do their own due diligence before investing in any securities mentioned in this article. Investing in securities is speculative and carries a high degree of risk. We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (“SEC”) at http://www.sec.govand/or the National Association of Securities Dealers (“NASD”) at We also recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at

Readers can review all public filings by companies at the SEC’s EDGAR page. The NASD has published information on how to invest carefully at its web site. The information found in this Newsletter is protected by the copyright laws of the United States and may not be copied, or reproduced in any way without the expressed, written consent of The SmallCap Network.


SmallCap Network

0 257


In reference to new research conducted by the RAND Corporation, kids who are privy to medical marijuana advertisement are more likely to use cannabis in the future. One typical worry among those hesitant to legalize cannabis is the question of what effect it potentially could have on the younger generation and this research has only stoked the fires of fear.

Published in the online journal Psychology of Addictive Behaviors, the research looked at 8,214 Southern California middle school kids that are in grade 6 through 8 from the year 2010 to 2011. Researchers asked kids in various forms of questions, involving questions about how often they have seen medical marijuana advertisement.

They discovered a major connection between children who had been exposed to advertisement promoted by medical marijuana companies with the intention of using marijuana in the future. Studies have shown that between the two years, the number of kids exposed to medical marijuana promotions went up from 22% to 30%.

However, researchers confess they cannot identify a definitive connection between medical marijuana advertisements and children who use pot, head researcher Elizabeth D’ Amico stated the results raise some interesting questions.

“As prohibitions on marijuana ease and sales of marijuana become more visible, it’s important to think about how we need to change the way we talk to young people about the risks posed by the drug,” D’Amico said. “The lessons we have learned from alcohol — a substance that is legal, but not necessarily safe — may provide guidance about approaches we need to take toward marijuana.”

0 376


When actor Jim Carrey co-opted the character of a distressed boy diagnosed with tuberous sclerosis complex (TSC) in an attempt to back up the actor’s perspective about vaccines, he inadvertently got people focused on TSC, which unlike vaccines, that have to do with autism. In utilizing the role of Alex Echols, for which actor Jim Carrey later apologized, Carrey may also have brought attention to another topic of conversation in autism circles: the use of cannabis as a therapy method.

Alex’s mother and father have a blog where they have written about Alex and his needs for many years. Among those needs, they go back and forth in a discussion about therapeutic cannabis, which they have said helps Alex with his self-injurious behaviors.
The Echols are not alone in their convictions abut cannabis as an intervention for neurological issues. A good amount of parents and some clinicians also have stated that the plant and its active chemical might provide an efficient treatment for some of these severe behaviors in correlation to autism and for schizophrenia, as well.

Just various other outlets of neuroactive compounds, marijuana has double the possibility to hold an advantage or become damaging, depending on which compound is the focus. One of its active ingredients, delta-9-tetrahydrocannabinol, otherwise known as THC, acts through a signaling system that incorporates some of the same components associated with a typical signaling in schizophrenia. In reference to Tori Rodriguez, writing at Psychiatry Advisor, research have displayed interesting parallels between altered brain function measures in individuals with schizophrenia and people who were under the influence of marijuana.

Thus, THC, it seems, is ‘pro-psychotic’ and there is a chicken-egg question about whether or not it adds to the growth or onset of psychosis reeled issues such as schizophrenia or if people with such symptoms might be more likely to reach out for it as self-medication.
The only known US Food and Drug Administration approved cannabis related medicine that is currently available is a synthetic version of THC, for alleviating nausea and vomiting related to various cancer treatments and weight loss in connection with AIDS. Though there is not much on the approved drug table for individuals who have schizophrenia.

0 410

Form 10-Q for PAZOO, INC.


Quarterly Report

Item 2 Management’s Discussion and Analysis of Financial Condition and Results of OperationsThis Quarterly Report on Form 10-Q contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements in this Quarterly Report that are not statements of historical facts are forward-looking statements, which involve risks and uncertainties. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” and similar expressions are intended to identify forward-looking statements. Our actual results may differ materially from those indicated in the forward-looking statements as a result of the factors set forth elsewhere in this Quarterly Report on Form 10-Q, including under “Risk Factors.” You should read the following discussion and analysis together with our unaudited financial statements for the periods specified and the related notes included herein. Further reference should be made to our Registration Statement on Form S-1 filed with the Securities and Exchange Commission.

This Quarterly Report on Form 10-Q contains terminology referring to Pazoo, Inc., such as “us,” “our,” and “the Company.”

Management intends the following discussion to assist in the understanding of our financial position and our results of operations for the three months ended March 31, 2015 and March 31, 2014.

Pazoo (“Pazoo”) was incorporated in Nevada on November 16, 2010 under the name “IUCSS, Inc.” A name change from IUCSS, Inc. to Pazoo occurred on May 9, 2011. We are a health and wellness company. Presently, our primary business is, an online, content driven, ad supported health and wellness web site for people and their pets. Additionally, this site has e-commerce functionality which allows to be an online retailer of nutritional foods/supplements, wellness goods, and fitness apparel. Pazoo, Inc. does not have any brick and mortar establishments. At present our only revenue source is which generates product sales and online advertising revenue. As of March 31, 2015, we had total assets of $323,111 and plan to make additional investments in online content.

The primary mission of is to deliver health and wellness content in the form of media, articles, blogs, videos and other media/content.
Additionally, delivers healthy cost-effective nutritional products based on relationships with leading manufacturers in the health improvement industry. In other words, is a user-friendly, attractively designed web site and e-commerce portal for total health and wellness information and health products for individuals and their pets. We seek to enhance visitors’ experiences to our website by providing total health content and health products including foods, drinks, supplements, wellness merchandise, and health/wellness advice.’s primary target demographic is health conscious adults ages 24 – 54 seeking to better their personal well-being and complement their daily lifestyles with consumer products items that are part of and promote a healthy lifestyle.

Our principal executive offices are located at 760 Route 10, Suite 203, Whippany, New Jersey 07981. Our telephone number is (855) PAZOO-US. Our internet address is

Sources of Revenue
We currently have three lines of business relating to and revolving around the health and wellness arena:

? Advertising Revenue from Our Website, Through advertising providers and agencies, is paid for every ad impression that appears on a page for which a visitor goes to. As we build our visitor base, ad revenue will increase. However, just having the traffic does not effectively increase advertising revenue. To get the full value of each visitor, the time on site must be long enough so that a visitor is interested in going to multiple pages for which there are ads on each page. The only way this will transpire is if the visitor’s experience is gratifying. This is why is so focused on quality content that’s interesting and informative. A bad visitor experience will result in a low time on site and fewer page views. Internet tracking tools have much improved over the past decade and will continue to improve in the coming years, especially when it comes to advertising and overall website analytics. Pazoo continues to constantly improve is this area at all times. has seen a strong increase in its viewership as shown by the recent average time spent on site for the period March 2014 to May 2014 of five minutes and forty seconds versus three minutes and twenty-seven seconds for the same time period from December 2013 to February 2014 with the same amount of page views. has a unique and compelling online marketing platform. offers the following important marketing advantages to its target audiences:

1. A comprehensive solution as a content source – information on a full spectrum of disciplines within the health and wellness marketplace;

2. Health and wellness experts that have expertise in these varied disciplines and write about their areas expertise; and

3. Content that is both for the health and wellness of people as well as their pets (over 60% of American homes have pets).

Table of Contents
? E-commerce. Our e-commerce offerings will increase as we build the traffic coming to In this way we could establish a revenue source over and above advertising to increase the value of each visitor. We have the following e-commerce elements ready for an activated marketing program:

1. An e-commerce platform that is functional;

2. Relationships with manufacturers, distributors and other e-commerce companies so that increasing product offerings will not be time consuming;

3. Members on the content team with merchandising experience: i.e. a Pazoo expert is buyer of pet products for a large pet retailer; and

4. Members on the content team that are experienced in e-commerce marketing; i.e. we will look to offer our consumers low cost and timely delivery of product by negotiating with shipping companies to offer a flat rates on various products.

? Pharmaceutical Testing Facilities. We entered this arena through our recent acquisition of a 40% minority equity stake in MA & Associates, LLC. MA & Associates was launched in September of 2013 to provide quality control services to the medical cannabis industry. MA & Associates’ primary mission is to protect the public health by providing infrastructure and analytical services to legally authorized distributors and producers of cannabis and to regulators tracking their operations.

The company will provide the medical cannabis industry guidelines on how the regulation and inspection by public health authorities is to be implemented. MA & Associates’ primary customer base includes all of the licensed cannabis cultivators, in the State of Nevada, and their customers are required by law to have their products tested before they can be transferred to the dispensaries. As such, we are in a unique position to provide the mandated health and safety testing upon which this burgeoning industry must hinge.

Critical Accounting Policy and Estimates Our financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to revenue recognition, accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

Results of Operations
Comparison of the three months ended March 31, 2015 to the three months ended March 31, 2014

Net Sales. We had net sales of $20,233 and $17,327 in the three months ended March 31, 2015 and March 31, 2014, respectively.

Cost of Goods Sold. We had cost of goods sold of zero and $325 in the three months ended March 31, 2015 and March 31, 2014, respectively.

Operating Expenses. Operating expenses consisted primarily of selling, general and administrative expenses and professional fees. Total operating expenses increased to $1,366,503 for the three month period ended March 31, 2015 from $264,299 for the three month period ended March 31, 2014. The components of operating expenses are detailed below.

Selling, General and Administrative expenses in the first three months of 2015 increased to $1,080,862 from $206,458 in the first three months of 2014. The increase was mainly comprised of stock compensation, and marketing & advertising.

Professional fees increased to $228,251 in the first three months of 2015 from $35,433 in the first three months of 2014. The increase in professional fees was attributed to an increase in investor relations and investor consultants.

Net Loss. Our net loss increased to $1,924,528 for the three months ended March 31, 2015 from $647,288 for the same period in 2014. The increase is primarily attributable to higher operating expense, as outlined above.

Liquidity and Capital Resources. In the three month period ended March 31, 2015, we had outstanding 501,850,585 common shares, 1,478,526 Series A Preferred Stock shares, 1,637,500 Series B preferred stock, and 580,000 shares of Series C Preferred Stock shares to fund business operations and invest in companies.

Our total assets were $323,111 as of March 31, 2015, which primarily consisted of intangible assets and $88,770 accounts receivable primarily for advertising revenue.

Table of Contents
We had negative working capital of $1,844,641 as of March 31, 2015.

Our total liabilities were $2,030,377 which was mainly comprised of derivative liability of $1,191,670 for our convertible notes and convertible debt of $621,133.

Our total stockholder’s deficit as of March 31, 2015 was $1,707,266 and we had a retained deficit of $9,344,477 through the same period.

We used $383,308 in net cash for operating activities for the three months ended March 31, 2015, which included a net loss of $1,924,528 and loss on derivative liability of $439,113.

We had $699,000 net cash used in investing activities in the three month period ended March 31, 2015 due primarily to investment in MA & Associates.

We had $365,880 net cash provided by financing activities in the three month period ended March 31, 2015 due primarily to borrowings on convertible notes and proceeds from sale of Series A preferred stock and warrants.

As of March 31, 2015, we had no formal long-term lines of credit or bank financing arrangements.

Off-Balance Sheet Arrangements. We have no off-balance sheet arrangements.

Subsequent Events.

In accordance with FASB ASC 855-10-50-1 we evaluated our subsequent events through June 17, 2015. Refer to Note 9, Subsequent Events, for detailed information.

0 202

PharmaCyte Biotech’s Dr. Mark Rabe Discusses the Significance of Schedule 1 License to Company’s Future in Cannabis Research

PharmaCyte Biotech (PMCB) announced this week that the Company is able to advance itsCannabis research now that its research partner, The University of Northern Colorado (UNC), successfully obtained a Schedule 1 license from the U.S. Drug Enforcement Agency or the DEA. This license will allow PharmaCyte Biotech to continue development of tumor-targeted treatments for serious and deadly cancers by utilizing cannabinoid prodrugs in combination with PharmaCyte Biotech’s signature live-cell encapsulation technology, Cell-in-a-Box®.

Dr. Mark L. Rabe, M.D., a member of PharmaCyte Biotech’s Scientific Advisory Board and a leading figure in the emerging medical Cannabis field, says this is great news for PharmaCyte Biotech. Stock Market Media Group (SMMG), a content development investment relations firm, discussed the issuance of the Schedule 1 license with Dr. Rabe and found that, for PharmaCyte Biotech, the license is truly significant to the company’s future work in the Cannabis arena.

SMMG: What does getting the Schedule 1 license mean for PharmaCyte Biotech?

Dr. Rabe: Issuance of the DEA Schedule 1 license is a big deal, and the application process was very rigorous. The license means that the federal government has taken a close look at what PharmaCyte Biotech and UNC researchers propose to do, along with its facilities, and has given permission to legally obtain Cannabis and its therapeutic molecular components in order to perform research.

Most importantly, the license provides PharmaCyte Biotech with a rare opportunity to develop “green” approaches to fighting deadly cancers, such as cancer of the pancreas, brain, and breast, which affect hundreds of thousands of individuals worldwide every year.

SMMG: What is the significance of a Schedule 1 license to the future work of a company like PharmaCyte?

Dr. Rabe: The license puts Pharmacyte Biotech and UNC into an elite group of U.S. researchers. With the ability to obtain government-approved Cannabis, work can now advance. Having the license provides credibility to the investigators, UNC, PharmaCyte Biotech, and ultimately the results, as they will be subject to peer review. And if all goes well, it should facilitate progression from bench science into preclinical studies and ultimately human clinical trials.

SMMG: How can PharmaCyte Biotech benefit from UNC being granted this license?

Dr. Rabe: PharmaCyte Biotech may advance its research on U.S. soil at a state institution that receives federal funding, with U.S. governmental approval and oversight. Not only does this allow this cutting-edge research to proceed, it should send a signal that the work has real potential.

SMMG: What is next for PharmaCyte Biotech with UNC now that the university has the Schedule 1 license?

Dr. Rabe: Until now, investigators have been using “model,” or “look-alike” compounds to develop protocols and screen various biological systems. With cannabinoid molecules in-hand, UNC researchers are now intently focused on reexamining the biological systems for activity as well as exploring additional systems suitable for use in combination with the Cell-in-a-Box®platform.

SMMG: Can you explain what it is PharmaCyte Biotech will do treatment-wise as a biotech company — medicinal versus medical Cannabis?

Dr. Rabe: The cannabinoid-based treatments that PharmaCyte Biotech is developing may be considered “medical Cannabis” in that “medical” treatments are being developed with molecules derived from the “Cannabis” plant. Otherwise, PharmaCyte Biotech falls squarely into the “biotech” category. Unrelated to Cannabis, the company has major programs underway using its unique Cell-in-a-Box® platform as a means to treat pancreatic cancer, malignant ascites (painful accumulation of fluid in the abdomen due to cancer) and diabetes.

When it comes to cannabinoids, PharmaCyte Biotech is optimizing the anticancerous effectiveness of these molecules in combination with Cell-in-a-Box® and a novel bioengineered human cell line. No one else is doing anything like this.

SMMG: What areas do you feel strongly that PharmaCyte Biotech can develop treatments for using cannabinoids?

Dr. Rabe: Cancer, for sure. Molecules such as tetrahydrocannabinol (THC) and cannabidiol (CBD) have been well documented in the medical literature to possess a number of anti-cancer properties including the ability to slow the growth of tumor cells and slow the penetration of blood vessels into tumors that allow them to metastasize. With Cell-in-a-Box®, those molecules can be generated right where they are needed at the site of a tumor — increasing their effectiveness and without the horrible side effects of conventional agents.

Pain is another important area for research. Pain affects over 100 million Americans and costs billions annually. Plant-based cannabinoid molecules, or “phytocannabinoids,” have been shown to relieve pain via three different mechanisms. Phytocannabinoids work because our bodies have a natural “endocannabinoid” system that regulates bodily systems and maintains homeostasis. Harnessing the power of the endocannabinoid system with a Cell-in-a-Box®approach to treat pain has some very interesting possibilities.

About Stock Market Media Group

Stock Market Media Group is a Content Development IR firm offering a platform for corporate stories to unfold in the media with research reports, corporate videos, CEO interviews and feature news articles. This article was written based upon publicly available information. PharmaCyte Biotech has not endorsed this article, and Stock Market Media Group was not compensated for its production.

Stock Market Media Group may from time to time include our own opinions about the companies, their business, markets and opportunities in our articles. Any opinions we may offer about any of the companies we write about are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice, or construed or interpreted as research. Any investment decisions you may make concerning any of the securities we write about are solely your responsibility based on your own due diligence. Our publications are provided only as an informational aid, and as a starting point for doing additional independent research. We encourage you to invest carefully and read the investor information available at the web site of the U.S. Securities and Exchange Commission at:, where you can also find all of PMCB’s filings and disclosures. We also recommend, as a general rule, that before investing in any securities you consult with a professional financial planner or advisor, and you should conduct a complete and independent investigation before investing in any security after prudent consideration of all pertinent risks.

We are not a registered broker, dealer, analyst, or adviser. We hold no investment licenses and may not sell, offer to sell or offer to buy any security. Our publications about any of the companies we write about are not a recommendation to buy or sell a security.

For more information:


Stock Market Media Group

0 244

Novus MedPlan Grows Its MMJ and Alternative Medicine Footprint

Novus Acquisition & Development Corp.(NDEV), developer of a cost-saving healthcare program called “Novus MedPlan” for patients within the medical marijuana (MMJ) and wellness industries, has made substantial progress over the past few months growing its provider network, launching its online platform, and garnering the media attention needed to help it reach scale.

In this article, we’ll take a closer look at some of these developments and where the company is headed over the coming quarters.

Provider Network Continues to Grow

Novus has expanded its long time Provider Network from Arizona and Colorado to now include Detroit, the Greater San Francisco area and Southern California.

Charlotte’s Web Update

Novus got approval from CB Botanicals and the Realm of Caring to offer its patient member base Charlottes Web, a low tetrahydrocannabinol (THC), high cannabidiol (CBD) cannabis extract. Novus patients can receive 5,000 milligrams for $695, representing a discount of 30%, a significant savings when considering the regular monthly use of the product to treat epilepsy in children.

Novus MedPlan Goes Live

Novus MedPlan officially launched its online platform on March 30th to connect medical marijuana and alternative medicine patients with participating dispensaries and providers through a seamless, real-time, and easy-to-use interface. By joining the network, members will have access to a large and growing provider network offering cost savings of 20% or more on over 1,000 products and services.

The platform has been built atop the Proteus420 dispensary management platform, which is the only real-time, fully-featured business solution that has been created specifically for the medical marijuana industry. Through the platform, patients can peruse various location, inventory and pricing before joining, quickly sign-up using valid MMJ permits, and select products with convenient pickup and delivery options.

For dispensaries, the platform enables easy monitoring of inventory, as well as the ability to change prices, adjust inventory levels, and load additional inventory within minutes. HIPPA-compliant data security, controlled employee access, and easy integration with other software platforms ensure that the solution can be conveniently added to existing business operations without a hitch.

Growing Consumer Demand

Novus has also been extremely active in creating awareness of the Novus MedPlan among potential users and establishing distribution channels to drive sign-ups. Priced at just $19.95 per month, the company’s program provides a compelling benefit to medical marijuana and alternative therapy patients, especially since the full costs can be recouped in just weeks with 20%+ discounts.

In February, the company signed an insurance sales agency contract with Senior Healthcare Benefits Group to market Novus MedPlan to registered medical marijuana patients in the state of Arizona in exchange for a flat 25% commission. With an outstanding application to expand sales into California, distribution channels like these could drive significant sign-ups over the coming quarters.

The company has also been generating a lot of press attention. In April, Novus MedPlan was featured in an editorial posted on the popular WeedMaps website, which has over 680,000 registered members and 10 million monthly page views. Exposure like this could help increase awareness of the Novus MedPlan with the MMJ patient population and ultimately drive sign-up growth over time.

Looking Ahead

The legal cannabis industry could reach as much as $21 to $35 billion by 2020, according toGreenWave Advisors, creating an enormous opportunity for numerous companies in the space. Some investors have focused on established companies, like GW Pharmaceuticals plc(NASDAQ:GWPH), while others have taken positions in smaller players, like Hemp Inc. (HEMP).

Those looking for heightened exposure, near-term revenue, and a unique niche with limited competition may want to take a look at Novus Acquisition & Development Corp. (NDEV). With a market capitalization of $8.7 million, the company may be significantly undervalued given its future potential. The stock also has a number of near-term catalysts as it continues to grow its membership base.

The company may also be interesting to investors in the traditional healthcare insurance space, including companies like Magellan Health Inc. (NASDAQ:MGLN) or Universal American Corporation (NYSE:UAM). In some cases, these investors may benefit from diversifying into a smaller company in a new burgeoning segment that’s currently out-of-reach for many existing companies in healthcare insurance.

For more information, visit the company’s website at

Legal Disclaimer:

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

SOURCE: Cannabis Financial Network

0 245

Lexaria Updates Sales Channels Efforts

 Lexaria, Corp. (LXRP) (CSE:LXX) (the “Company”) provides the following information regarding sales channels that the Company is developing.

Lexaria has to date sold small but increasing amounts of ViPova(TM) Tea through the ViPova website. The Company has certain marketing strategies under development that could result in meaningful increased awareness and product sales prior to the end of the Company’s fiscal year (August 31).

To facilitate our sales, Lexaria has signed an agreement with a sales organization that specializes in sales to the medical marijuana dispensary industry. Direct sales representatives’ initiatives are to commence next week. The professional salespeople will introduce Lexaria products, beginning with ViPova(TM) Tea and gradually introducing additional products as they become available. The focus of these sales efforts will be leading medical marijuana dispensaries, where customers are generally already informed of the beneficial properties of cannabidiol.

ViPova(TM) Tea is now available at a small number of retail and online locations. We expect to soon have additional online and retail locations where ViPova(TM) is available, and will announce all these locations soon. Lexaria has also begun welcoming affiliate sales people who are having increasing success selling the product both to individuals and to retail locations.

Lexaria has also continued efforts to make ViPova Tea available at and is awaiting a decision from Amazon regarding this sales channel, which has taken more time than expected.

Lexaria has also identified a particular health & fitness vertical sales channel that management believes will be very receptive to our CBD-fortified products, and is preparing a large marketing and sample provision campaign to this industry this summer, focused to start on Western US states. One particularly interesting aspect of this sales channel is that Lexaria currently has virtually no competition within it, since those companies that produce THC containing products are not permitted to sell within this channel in general. Lexaria’s products, using our proprietary patent-pending CBD infusion process, are uniquely positioned to deliver CBD through popular food and beverage categories.

Coordinated with our sales initiatives are our product development programs: we want our salespeople to have the ability to sell several unique food products sooner rather than later. Product development in the areas of hot chocolate, coffee, flavored teas and energy bars is all ongoing at this time.

About Lexaria

Lexaria is a food sciences company focused on the delivery of cannabinoid compounds procured from legal, agricultural hemp, through gourmet foods based upon its proprietary infusion technologies.

About ViPova(TM)

ViPova(TM) uses only legal CBD oil extracts, grown from agricultural hemp in locations where it is legal to do so, in ViPova(TM) -branded tea. ViPova(TM) uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPova(TM) has this ground-breaking technology for CBD/lipid infusion.


Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424


This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any planned corporate activity, business venture, or initiative will be pursued, or if pursued, will be successful. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. There is no assurance that the cannabinoid/lipid infusion technology will provide any increase in bioavailability to any individual person. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPova(TM) products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

SOURCE: Lexaria Corp.

0 294

Oxis Biotech Files U.S. Patent Application Covering p62/Sequestosome 1 Inhibitors For The Treatment Of Multiple Myeloma And Secondary Osteolytic Lesions

Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] announced today it has filed a U.S. patent application covering additional analogs of the company’s lead compound, OXS-4235, a potent p62/Sequestosome 1 (p62) inhibitor.  These novel p62 inhibitors demonstrate inhibition of multiple myeloma cell growth without toxicity to normal bone marrow stromal cells.  Bone marrow stromal cells are involved in hematopoiesis and certain inflammatory processes.

Multiple myeloma is a type of cancer that forms in white blood cells, and affects about 26,850 people annually in the USA causing about 11,240 deaths per year.  Multiple myeloma causes cancer cells to accumulate in the bone marrow, where they crowd out healthy blood cells.  Multiple myeloma is also characterized by destructive osteolytic bone lesions (rounded, punched-out areas of bone), diffuse osteoporosis, bone pain, and the production of abnormal proteins which accumulate in the urine.  Plasma cell leukemia, a condition in which plasma cells comprise greater than 20% of peripheral leukocytes, is typically a terminal stage of multiple myeloma and is associated with short survival.

Multiple myeloma is marked by abnormal protein production, and frequently is characterized by bone disease – a major cause of patient morbidity.  Multiple myeloma induced bone disease is marked by holes in the bone and intense pain due to increased osteoclast bone degradation activity and highly suppressed or absent osteoblast bone remodeling (growth) activity.  Cell adhesive interactions between multiple myeloma cells and bone marrow stromal cells activate multiple signaling pathways that enhance cancerous tumor growth and bone destruction while suppressing new bone formation and contributing to drug resistance.

The recent improvements in overall survival and remission duration in multiple myeloma are largely due to the advent of novel therapeutic agents.  These therapeutic agents exploit a tumor cell’s dependency on clearance mechanisms for abnormal or mutant cellular proteins.  Tumor cells are very sensitive to any type of inhibition of this clearance mechanism which when inhibited leads to an antiproliferative and pro-apoptotic effect on the tumor cells mediated by induction of endoplasmic reticulum stress, activation of caspases, and generation of reactive oxygen species.

p62 is a protein having multiple biological roles involving cell signaling, cell receptor internalization, and protein degradation/turnover.  p62 has been reported to be a regulator of inflammation, neurogenesis, increased osteoclastogenesis (bone destruction), adipogenesis and T-cell differentiation.  One of the more interesting functions of p62 is the regulation of NF-kappa-B, which is the master regulator of innate immunity and aging.  p62 is also found in inclusion bodies containing polyubiquitinated protein aggregates which are present in several neurodegenerative diseases such as Parkinson, Alzheimer, and Huntington’s diseases.  Additionally, p62 acts as s shuttling factor for the delivery of damaged biomolecules to the proteasome for destruction and removal.

By selectively inhibiting p62 in multiple myeloma cancer cells, stress is induced in the multiple myeloma cancer cells due to the accumulation within the cells of damaged biomolecules that cannot be destroyed via the normal function of the proteasome.  As a result of the stress placed on the cancer cells by inhibition of p62, the cancer cells undergo a biological process known as autophagy which results in their destruction.

OXS-4235 is a first-in-class therapeutic candidate targeting the inhibition of p62 for the treatment of multiple myeloma and osteolytic lesions.  In in vitroand in vivo models of multiple myeloma and osteoporosis, OXS-4235 demonstrated the ability to kill multiple myeloma tumors, decrease osteolytic lesions, and the ability to help restore normal bone remodeling resulting in healthy bone.  In addition to direct killing of multiple myeloma cells, OXS-4235 was found to also inhibit TNF-alpha mediated osteoclast formation.  TNF-alpha is a major suppressor of osteoblast differentiation.  TNF-alpha is upregulated in the bone marrow microenvironment resulting from multiple myeloma cell – stromal cell interactions.  Reducing osteoblast suppression in the multiple myeloma bone marrow microenvironment via the inhibition of TNF-alpha, normal bone remodeling is restored.

“OXS-4235’s dual mechanism of action, and no observed toxicity in mouse models of multiple myeloma is very exciting”. Our drugs ability to increase bone density while shrinking tumors, which is a major problem with Multiple Myeloma patients, Makes this a first of its kind, as there are no other drugs with this dual mechanism of action (approved or not approved) that have this ability, stated Anthony Cataldo, Chairman and Chief Executive Officer of Oxis Biotech, Inc.

About Oxis Biotech, Inc.

Oxis Biotech is a cancer immunotherapy company developing innovative therapies focused on the treatment of cancer.  Oxis’ immunotherapy platform includes bispecific immune cell engagers, antibody-drug conjugates (ADCs), and novel small molecule therapeutics targeting B-cell malignancies and certain solid tumors such as triple negative breast cancer.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially.  Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results.  Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company’s ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Jonathon Barkman
Riverview Capital Enterprises

To view the original version on PR Newswire, visit:

0 365

Totally Hemp Crazy Inc. Announces Harry Drnec Named as Advisory Director

 Totally Hemp Crazy Inc. (OTC PINK: THCZ) announced today the appointment of Harry Drnec as Advisor to the Board of Directors. Mr. Drnec brings a world of experience in new product development and product launching; experience he developed under a diverse repertoire of beverage companies. He is the former Managing Director of Red Bull UK. At Red Bull, Mr. Drnec lifted a failing brand, impacting sales from 3M cans in 1996 to 300M cans in 2006. He was also the Brand Manager that launched the largest selling beer brand in the world, Bud Light, with Anheuser Busch, later launching Budweiser and Michelob across Europe. Mr. Drnec also served as a Senior Marketer for Ernest and Julio Gallo. Over the next few months, THCZ will formulate a total marketing plan for the Company under the guidance and expertise of Mr. Drnec.

Mr. Drnec stated, “I am extremely excited about this new segment of the drink industry, and I love the direction that Rocky Mountain High is taking.”

Jerry Grisaffi, Founder of THCZ, remarked, “We are very excited to welcome Mr. Drnec to our company and look forward to capitalizing on his wealth of knowledge of the beverage industry.”

Rhino Marketing was appointed by THCZ to build and manage their global marketing platform and launch strategy. Rhino Marketing CEO, Thomas Hensey, exclaimed, “Harry has been a mentor of mine for years, and I cannot express in words just how pleased I am to now be working hand in hand with Harry on the marketing of the Rocky Mountain High brand line-up.”

Totally Hemp Crazy Inc. will be featured on a national radio show, Your Monies Worth, on Friday, May 15th at 12:00 noon Eastern Time. Tom Shuman, CEO of THCZ and Jerry Grisaffi will be interviewed by longtime radio host, Mick Bazsuly of WWNN AM Miami-Fort Lauderdale.

The interview will be aired live worldwide on: and

The webcast can be found at: and

The radio show, Your Monies Worth has been continuously aired for thirteen years and is centered on interesting growth companies with unique potential.

About Totally Hemp Crazy Inc.:

Totally Hemp Crazy manufactures Rocky Mountain High hemp beverage infused drinks – a range of wickedly delicious hemp based beverages that is 100% legal and refreshing!

Visit us at:

Visit us at:

Visit us at Investor Hangout:

Safe Harbor Act:
This release includes forward looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involves risks and uncertainties including, but not limited to, the impact of competitive products, the ability to meet customer demand, the ability to manage growth, acquisitions of technology, equipment, or human resources, the effect of economic business conditions, and the ability to attract and retain skilled personnel. The Company is not obligated to revise or update any forward looking statements in order to reflect events or circumstances that may arise after the date of this release.


Jerry Grisaffi
Email Contact

Investor Relations:
The Eversull Group, Inc.
Jack Eversull
Email Contact

0 554

If any person was born after 1983 they have most likely encountered a D.A.R.E representative. Typically local law enforcement will visit sixth-grade classrooms with charts, reports and commonly freighting, and more times than not erroneous, information about drugs. The effectiveness of the D.A.R.E. program which was initiated by the late ex-LAPD chief Daryl Gates, has been presented obstacles over the years and currently with a thorough investigation conducted by the National Center for Biotechnology Information has came to the result that D.A.R.E. is ineffective.

It looks like D.A.R.E. has gone full circle and is a joke… or at least can determine what a joke is.
“Marijuana candies, sold on the street as ‘Uncle Tweety’s Chewy Flipper’ and ‘Gummy Satans’ are taking the country by storm,” an interesting read on D.A.R.E.’s website recently.
When a writer for the Washington Post Wonkblog called to find out about the posting, D.A.R.E. immediately took it off their site with no comment, however, the story was kept by the Internet Archive.
And it only gets better.
“It is sad that in a country as developed as America, such third world drugs such as marijuana are allowed to exist,” the different story’s anonymous author wrote. “Children are being addicted to marijuana. I knew this day would come when a liberal president allowed a state to legally sell Marijuana Flintstone Vitamins to children.”
The fake article continued to make outright preposterous claims, which D.A.R.E. reposted every word in a panicked attempt to hold on to any articles displaying the cons of cannabis
“Marijuana. It is one of the most dangerous drugs on Earth.”
“For every one joint of marijuana, four teenagers become burdened with pregnancy.”
Violent offenses, fits of primal aggression, heart issues, low testosterone, heart conditions, COPD, are all the conclusions of using cannabis, according to the very funny satirical posting.
Back in 2012, the Obama administration terminated the “national Drug Abuse Resistance Education Day” however D.A.R.E. still obtains funding from the Justice Department, and various other government agencies, foundations and corporations.

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact